Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer - Wikidata - awgldk - TriplyDB

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

http://www.wikidata.org/entity/Q34156513

about

Crizotinib resistance: implications for therapeutic strategies Targeted therapies and immunotherapy in non-small-cell lung cancer Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases A functional landscape of resistance to ALK inhibition in lung cancer.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer Global survey of the immunomodulatory potential of common drugs.Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.Resisting Resistance: Targeted Therapies in Lung Cancer.Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells.ALK: a tyrosine kinase target for cancer therapy.iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes.Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Minireview: Were the IGF Signaling Inhibitors All Bad?Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival.

P2860

Q26738381-1926DCDC-C250-4CFE-9C11-B51710238E03 Q26738986-E36B0A32-1F70-4DBD-AC0D-BB5F59645582 Q26740210-DB310742-78A6-48EE-877B-45D7A505CAAE Q26740329-23EF0096-278A-434F-A42B-A049EFE41BEC Q26768158-591C943B-BB3F-4DFE-BB17-1464425FE164 Q26769659-B3228BDB-CC37-427C-B53D-23D36728C704 Q26795555-E7D1A967-E216-41D1-92B3-17D7D194EFE9 Q26824877-65EAFA7B-32DF-47DD-993A-43693C27924C Q27687709-4A0B3627-FA4F-4D0F-AE64-960D21299E19 Q27853299-D1A465B8-A8AA-48D0-A223-85AB383F0901 Q28068643-18F2AAA6-1910-4F8E-B776-8F7EB76093EB Q28546245-1E144C97-3D99-4490-8E6D-6A432E7AEC03 Q30384542-66C323F2-A2EB-4162-A174-0B9CDE154141 Q31141961-2FBB4470-3273-4FA8-8D9F-4437C20465A5 Q35438912-52DC7827-ACCB-4B46-A24A-B54311289EF6 Q35858617-1FAF5297-9AF3-4BFF-B2DD-DB598C7C868E Q36066539-12A921B5-D9BB-4330-8BCD-013B0B602A50 Q36104980-C201FC1D-9FD1-4EB9-97A9-1E74A9DC7255 Q36260477-66461AD6-1A20-4198-B169-8FA53CF67D1A Q36355056-38AEDF9C-E4BD-4A02-8BA7-6802FADBE39D Q36387216-2A151906-9C6A-4280-BC4C-984156885304 Q36525647-3A6404BE-D65F-490D-9D90-72ED2DA8EE65 Q36538788-A2A6156E-9049-4AD3-90E0-13FCFB491D78 Q36772120-8786FA5F-BBC0-485F-B4F4-65F73CE81AA0 Q37017020-A342D8B5-1808-4E0F-9EED-FD11E6A388AE Q37096363-DFADFE04-ECD5-423C-96E0-0579404BCC2B Q37376294-D3F2CC21-14EA-4C50-830E-3184E7F9D7D8 Q37388238-97A15617-773B-4F5E-8178-1E5C9EC48396 Q37466518-C27EEC16-86A5-4B2A-AAB8-C9E14850DF5B Q37518624-8D8BB609-713D-421C-94AF-205D30ED9896 Q37529618-F158F28F-9B00-493D-8115-5880E5708A6B Q37592115-3BD66C16-C86C-4E93-B4CF-B9DE1B4A3946 Q37666880-4643BC58-0EE9-480E-94F0-58A13CFCD982 Q38355156-6DD601AF-5A09-4280-8C37-B1E65032A264 Q38459398-789F04B0-04CD-472B-A62D-992EA97C7D7E Q38484053-7BB38FBD-0A4E-4F7B-9EF3-9E87F5FB882F Q38576015-2E69308A-6767-49FF-8222-437F6E8E62CC Q38586367-185C642D-4A97-4AC0-A8BD-CC4B08FB48B2 Q38641329-614254CB-381C-47C3-9016-5E447D350DD5 Q38663388-6199EACC-3A82-465B-8035-20D67A1F2BD0

P2860

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

http://www.wikidata.org/entity/Q34156513

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@ast

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@en

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@nl

type

label

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@ast

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@en

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@nl

prefLabel

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@ast

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@en

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@nl

P1433

Q34156513-6BD82042-D2AF-40DA-8430-673E86A248E9

P1476

Q34156513-787FC9B3-5896-4B9A-BF42-7309DD73D551

P2093

Q34156513-0C2BA55E-6B7D-45B5-8D90-AFBC3FC6C381

Q34156513-113CBF58-1DBA-4A5C-8D50-A61A4E6A7258

Q34156513-175D16EC-592E-424D-A09A-B70BEC19F35E

Q34156513-1A3A09E1-7AA8-4EC5-9C40-F6DF2B8B6B5D

Q34156513-2805B656-8E8F-459D-AE31-F9B6B2F4A31A

Q34156513-2FD724CB-1ED3-48AE-BAD1-1AFC873FCA60

Q34156513-376FA76D-2B2D-4E2A-87A6-908A6C97AEFB

Q34156513-473F2739-2353-4685-AA0D-259F9B13A2E7

Q34156513-49730CD6-4024-49BE-848D-EBC22B2AEE8A

Q34156513-692CB843-9BFE-4F1B-8F7F-2DECAA779C9F

P2860

Q34156513-0118D039-CAE0-4869-B7D6-9C322E1C3542

Q34156513-0E0E86BF-9F7F-408B-A0F4-507AFBFEE523

Q34156513-1672566B-55D2-4C48-9C1B-BD60C9C5F139

Q34156513-356EE90A-87E3-4991-83EE-6C28B7001569

Q34156513-38B0C68E-FB1B-4F86-85DD-88CEAFC35DD7

Q34156513-3CAFB553-335D-4FDE-AFCF-6B6D4849ED11

Q34156513-4660F3F5-C8DC-4236-8D06-E2C123A14BD5

Q34156513-4A72D109-0E76-4965-A95E-A11C7EA51845

Q34156513-4E23C0AA-83E2-4E7C-A668-A485E757BC27

Q34156513-55CE125A-4B42-455A-8E9E-4D45780FEF87

P2888

Q34156513-93E50425-9A2C-4591-8CE5-B81B3F26A77D

P304

Q34156513-199FA7F9-D6C3-4767-9A25-0AAA0B375332

P31

Q34156513-EC653943-38BF-4CE7-879C-6719D2584E4F

P356

Q34156513-DF642DFD-D0A7-431C-A178-9D5C4E58DF06

P407

Q34156513-C7774131-5CE9-4F0F-B8CB-C2860207A968

P433

Q34156513-69AB1F86-82E3-4F7B-BAA5-57E52C0650FA

P478

Q34156513-377AC4F9-10F2-4D00-89D5-752C42F68BF0

P50

Q34156513-0839ED8D-BD44-4D66-87C1-F33B6CA81972

Q34156513-2620BF49-BA29-4CB7-B2FD-C82F172D9D08

Q34156513-483607CA-88CF-46F2-93CF-B9725A282CA7

Q34156513-6A3D5B46-D604-4B82-9C79-25521CA9389C

Q34156513-D704D1AA-A037-48B3-A529-4B7D3009B1BF

Q34156513-D8138EA1-9A1F-4BDC-8371-2C392A6C631D

Q34156513-FF0C5F35-0548-4DEE-92CD-1599F7678C00

P577

Q34156513-69E169E8-9D6C-408F-BA70-32882AFE3CF1

P698

Q34156513-C718D0A9-28EB-4685-A291-F74F3F6ECE49

P932

Q34156513-E517FA41-4470-4B60-81F7-1A5FBB3DE122

P356

P1433

Nature Medicine

P1476

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

@en

P2093

Alexandra Florin

http://www.w3.org/2001/XMLSchema#string

Benjamin Solomon

http://www.w3.org/2001/XMLSchema#string

David H Johnson

http://www.w3.org/2001/XMLSchema#string

Diana Lim

http://www.w3.org/2001/XMLSchema#string

Hailing Jin

http://www.w3.org/2001/XMLSchema#string

Heidi Chen

http://www.w3.org/2001/XMLSchema#string

Jürgen Wolf

http://www.w3.org/2001/XMLSchema#string

Leora Horn

http://www.w3.org/2001/XMLSchema#string

Lu Wang

http://www.w3.org/2001/XMLSchema#string

Luka Ozretić

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing identifies a basis for everolimus sensitivity

Fast and accurate short read alignment with Burrows-Wheeler transform

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

The Sequence Alignment/Map format and SAMtools

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

beadarray: R classes and methods for Illumina bead-based data.

P2888

P304

1027-1034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3667

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Elisa de Stanchina

Christine M. Lovly

P577

2014-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25173427

http://www.w3.org/2001/XMLSchema#string

P932

4159407

http://www.w3.org/2001/XMLSchema#string